Biomea Fusion, Inc.
BMEA · XNASCIK 1840439fmd_0BP4JQAM511SRN4B2N0J8EHKX6Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 28 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Net interest income | – | – | – | – | 9 | 6 | 2 |
| Research and development | 1 | 4 | 28 | 63 | 103 | 118 | 62 |
| Total operating expenses | 1 | 5 | 42 | 84 | 126 | 144 | 84 |
| Operating income | (1) | (5) | (42) | (84) | (126) | (144) | (84) |
| Interest and investment income | – | 0 | 0 | 2 | 9 | 6 | 2 |
| Income tax expense | – | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (1) | (5) | (42) | (82) | (117) | (138) | (62) |